Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation

NCT04140409 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped Slow recruitment

Conditions

Neuroendocrine Tumors
Carcinoid Syndrome

Interventions

DRUG: Sandostatin

Sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain